In Vivo Sp. z o.o.

Bydgoszcz 55 trials 26 recruiting

55 Registered trials

26 Currently recruiting

Organisation

In Vivo Sp. z o.o.

Location

Bydgoszcz, Poland

Identifier

ORG-100042782

Address

Ul. Kaszubska 17h, 85-048, Poland

Departments

3020:Cardiology
5705: Hematology
616001: IN-VIVO Bydgoszcz
Gynaecology
IN VIVO
In Vivo Sp. z o.o
In Vivo Sp. z o.o.
In-Vivo Bydgoszcz
N/A
N/D
NA
NA/ND
not applicable
Oncology
Ośrodek Badań Klinicznych In Vivo Sp. z o.o.
Specjalista hematolog
Urologia

Clinical trials at this site (55)

Search interface

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chro… Recruiting

2023-508005-24-00 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5 2024-08-01
A study comparing TAR-210 versus single agent treatment instilled directly into the bladder in people with bladder cancer with FGFR gene alt… Recruiting

2023-507684-19-00 FGFR+ Intermediate-risk Non-muscle Invasive Bladder Can 5 2024-07-24
A Trial to Learn if Odronextamab Combined with Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined … Recruiting

2022-502113-28-00 Follicular lymphoma 5 2024-02-01
A trial to learn if odronextamab combined with lenalidomide is safe and works better than rituximab combined with lenalidomide in adult part… Recruiting

2022-503092-28-00 Relapsed/Refractory Follicular Lymphoma 5 2024-01-08
A Randomized, Multi-Center, Parallel, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics o… Recruiting

2022-502193-16-00 Chronic lymphocytic leukemia, Multiple Myeloma and Non- 5 2023-11-14
Iberdomide Manteinance Versus Lenalidomide Manteinance Therapy Following Autologous Stem Cell Transplant in Participants with NDMM Recruiting

2022-501515-14-00 Newly Diagnosed Multiple Myeloma (NDMM) 5 2023-09-29
A Study in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment with Pozelimab + Cemdisira… Recruiting

2023-510336-36-00 Paroxysmal nocturnal hemoglobinuria (PNH) 5 2023-05-05
Mevrometostat Treatment Of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma Recruiting

2023-509179-18-00 Castration Resistant Prostate Cancer (CRPC) 1 2019-08-13
A Phase 2 Study of Dexlansoprazole Delayed-Release Capsules to Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Pediatric Sub… Ended

2022-501349-64-00 Symptomatic nonerosive GERD in paediatric subjects aged 4 2026-01-12
Study of the Safety and lmmunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, T… Ended

2024-512271-13-00 Pneumococcal immunisation 5 2025-05-08
Safety and immunogenicity of an investigational Pentavalent Meningococcal ABCYW vaccine against meningococcal disease in children, toddlers,… Ended

2023-510465-10-00 Meningococcal immunization 4 2025-03-10
A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women with Breast Cancer Who Are Having Hormone Therapy Ended

2024-510719-31-00 Moderate to Severe Vasomotor Symptoms (VMS) 5 2025-01-24
Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women with Recurrent Vulvovaginal Candidiasis: A Randomize… Ended

2023-507527-28-00 Recurrent vulvovaginal candidiasis 7 2024-09-16
A Phase 3, Randomized, Open-label, Multi-center Study Evaluating the Efficacy and Safety of TAR-200 Versus Investigator’s Choice of Intraves… Ended

2023-507685-10-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2024-05-30
A Study of Susceptibility to Baloxavir Marboxil in Patients with Influenza and its transmission to their household contacts Ended

2023-504672-22-00 Influenza 5 2023-11-24
Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended

2023-503265-27-00 Participants with Untreated T4N0 or Stage III dMMR/MSI- 5 2023-11-23
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 … Ended

2023-507187-39-00 High-Risk Non-muscle-invasive Bladder Cancer 5 2023-03-23
A Phase III Open-Label Trial of Acalabrutinib Plus Venetoclax versus Venetoclax plus Obinutuzumab in Previously Untreated Chronic Lymphocyti… Ended

2023-505866-27-00 Chronic Lymphocytic Leukemia or Small Lymphocytic Lymph 5 2022-10-28
MagnetisMM-5: A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dex… Ended

2023-509208-14-00 MULTIPLE MYELOMA 5 2021-09-28
A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended

2023-506365-64-00 Deleterious Germline or Somatic Homologous Recombinatio 5 2020-10-16
A research study to look at how semaglutide compared to placebo affects diabetic eye disease in people with type 2 diabetes (FOCUS) Ended

2023-506827-26-00 While it is well-established that long-term good glycae 5 2019-05-02
This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre… Ended

2023-509349-11-00 Previously untreated Chronic Lymphocytic Leukemia Witho 5 2019-03-22